Tekla Capital Management LLC Has $12.37 Million Position in SPDR S&P Biotech ETF (XBI)

Tekla Capital Management LLC lessened its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 48.5% during the third quarter, HoldingsChannel.com reports. The firm owned 129,000 shares of the exchange traded fund’s stock after selling 121,460 shares during the quarter. Tekla Capital Management LLC’s holdings in SPDR S&P Biotech ETF were worth $12,367,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Valeo Financial Advisors LLC increased its position in shares of SPDR S&P Biotech ETF by 165.2% in the second quarter. Valeo Financial Advisors LLC now owns 1,525 shares of the exchange traded fund’s stock valued at $144,000 after acquiring an additional 950 shares during the period. Moneta Group Investment Advisors LLC purchased a new position in shares of SPDR S&P Biotech ETF in the second quarter valued at about $144,000. Mainstay Capital Management LLC ADV increased its position in shares of SPDR S&P Biotech ETF by 9,419.3% in the second quarter. Mainstay Capital Management LLC ADV now owns 14,279 shares of the exchange traded fund’s stock valued at $150,000 after acquiring an additional 14,129 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of SPDR S&P Biotech ETF in the third quarter valued at about $153,000. Finally, Cypress Capital Management LLC WY increased its position in shares of SPDR S&P Biotech ETF by 51.8% in the second quarter. Cypress Capital Management LLC WY now owns 2,065 shares of the exchange traded fund’s stock valued at $197,000 after acquiring an additional 705 shares during the period.

Shares of XBI stock traded up $2.48 during mid-day trading on Monday, reaching $84.13. The stock had a trading volume of 108,256 shares, compared to its average volume of 4,860,788. SPDR S&P Biotech ETF has a 52-week low of $73.97 and a 52-week high of $101.55.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.com-unik.info/2018/12/03/tekla-capital-management-llc-has-12-37-million-position-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Derivative

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit